Creative Biolabs Powers up Disease-specific Oncolytic Virotherapy DevelopmentPosted by beauty33 on October 21st, 2021 Oncolytic viruses have long been viewed as tools for killing cancer cells, and Creative Biolabs excels in disease specific oncolytic virotherapy development services, aiming at assisting worldwide scientists with related researches. Oncolytic virus use has grown significantly in recent years, with interest in it reaching new heights as a result of recent scientific breakthroughs and investments. Oncolytic virotherapy appears to be a viable treatment option for cancer treatment, and to develop oncolytic viruses (OVs) as a tool to regulate the immune system response, several in vitro and in vivo research have been done and are still underway. As a leading biotechnology company, Creative Biolabs announces productions and services of one-stop oncolytic virotherapy development, covering a wide range of cancer, such as melanoma, genitourinary, gastrointestinal cancers, hepatocellular carcinoma, gynecologic malignancies, breast cancer, lung cancer, head and neck cancer, brain tumors, etc. Melanoma is a kind of skin cancer caused by cells named melanocytes, one of the common cancers and of great risk for its ability to spread to other organs rapidly. In order to promote the application of OVs in the treatment of melanoma, Creative Biolabs has developed an OncoVirapy™ platform, providing a full range of oncolytic virotherapy development services from OV construction to function validation both in vitro and in vivo. In the whole process, the scientist team not only cares about the antitumor efficacy, but also takes safety and other clinical issues into account. In a review of the top 10 causes of death in men, bladder cancer is eighth and renal cancer is tenth. These two kinds as well as penis cancer and testicle cancer are all called genitourinary (GU) malignancies. For oncolytic virus development of GU cancers, Creative Biolabs provides virus vector construction and validation services on the basis of genetic mutations, virus tropism and arming virus. Beyond the aforementioned options, more strategies are available, such as combination of oncolytic virus with gene therapy, coat modification of oncolytic virus, and delivery of oncolytic virus with carrier cells.
Gastrointestinal (GI) cancers refer to malignant conditions of the gastrointestinal tract and organs of digestion, and OVs continue to hold promise as an effective treatment. With accumulated experience, scientists at Creative Biolabs are skillful in developing oncolytic virotherapy for GI cancers, especially for gastric cancer and pancreatic cancer. Based on the experienced team consisting of scientists of Ph. D level and dedicated managers, Creative Biolabs is confident in providing novel OVs and developing more efficient oncolytic virotherapy strategies to facilitate the research of global scientists. Further information can be found on: https://www.creative-biolabs.com/oncolytic-virus.
About Creative Biolabs With years of study and experience in cancer immunotherapy development and virotherapy, Creative Biolabs, a leading company providing customized, standardized, reliable and high-quality oncolytic virus therapy development services, offers one-stop services covering oncolytic virus design and construction, engineering, in vitro and in vivo validation for various types of tumors, and for combination with other therapies. Like it? Share it! More by this author |